Under the agreement, TRL and Anaphore will generate novel trivalent proteins called Atrimers that can be programmed to bind to and activate or inhibit targets of interest.
The partnership will focus on strategies to develop biologic therapies for autoimmune disorders such as, rheumatoid arthritis, inflammatory bowel disease, and psoriasis.
TRL and Anaphore will commence the research and development alliance immediately.
TRL chief scientific officer Roland Newman said that this collaboration with Anaphore will allow TRL to consolidate its position in autoimmune disease research and allow us to bring a new generation of biologics to physicians and their patients.